Patents by Inventor Jiazhou Qiu

Jiazhou Qiu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IGA1 protease polypeptide agents and uses thereof
    Patent number: 8841109
    Abstract: Polypeptide agents useful in the treatment of IgA1 deposition diseases and methods of using such polypeptide agents. Methods of screening for inhibitors of IgA1 proteases and agents that inhibit IgA1 proteases are also disclosed.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: September 23, 2014
    Assignees: The University of Kansas, Tufts Medical Center, Inc.
    Inventors: Todd Holyoak, Jiazhou Qiu, Andrew G. Plaut
  • Clearance of abnormal IGA1 in IGA1 deposition diseases
    Patent number: 8440191
    Abstract: The present invention relates to proteins which specifically bind to IgA1 and which have been modified to comprise either O- or N-linked glycans. The invention encompasses methods for decreasing IgA1, preferably abnormally glycosylated IgA1, in an individual by administering to the individual a glycan-modified IgA1 binding protein of the invention. The invention also encompasses a method for the treatment of a disease characterized by IgA1 deposition wherein a glycan-modified IgA1 binding protein is administered to an individual in need thereof.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: May 14, 2013
    Assignee: Tufts Medical Center
    Inventors: Andrew G. Plaut, Jiazhou Qiu
  • METHODS AND COMPOSITIONS FOR DIAGNOSIS OF IGA-AND IGM-MEDIATED KIDNEY DISEASES
    Publication number: 20130095036
    Abstract: The present invention features noninvasive methods for diagnosing IgA or IgM kidney disorders, such as IgA nephropathy, Henoch-Schönlein purpura, and IgM nephropathy, in a mammal. The invention also features compositions and kits useful in diagnosing these disorders.
    Type: Application
    Filed: April 4, 2012
    Publication date: April 18, 2013
    Applicants: New England Medical Center Hospitals, Inc., RQ Bioscience, Inc.
    Inventors: Robert Qiu, Jiazhou Qiu, Andrew G. Plaut
  • Combination therapy with IgA1 proteases
    Patent number: 8216568
    Abstract: The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are provided. In particular, therapeutic agents to treat IgA nephropathy, Dermatitis herpetiformis (DH), and Henoch-Schoenlein purpura (HS) are disclosed.
    Type: Grant
    Filed: July 21, 2008
    Date of Patent: July 10, 2012
    Assignee: Tufts Medical Center
    Inventors: Andrew G. Plaut, Jiazhou Qiu
  • IGA1 PROTEASE POLYPEPTIDE AGENTS AND USES THEREOF
    Publication number: 20120114629
    Abstract: Polypeptide agents useful in the treatment of IgA1 deposition diseases and methods of using such polypeptide agents. Methods of screening for inhibitors of IgA1 proteases and agents that inhibit IgA1 proteases are also disclosed.
    Type: Application
    Filed: April 20, 2010
    Publication date: May 10, 2012
    Applicant: TUFTS MEDICAL CENTER, INC.
    Inventors: Todd Holyoak, Jiazhou Qiu, Andrew G. Plaut
  • Methods and compositions for diagnosis of iga-and igm-mediated kidney diseases
    Publication number: 20100015044
    Abstract: The present invention features noninvasive methods for diagnosing IgA or IgM kidney disorders, such as IgA nephropathy, Henoch-Schönlein purpura, and IgM nephropathy, in a mammal. The invention also features compositions and kits useful in diagnosing these disorders.
    Type: Application
    Filed: August 3, 2006
    Publication date: January 21, 2010
    Inventors: Robert Qiu, Jiazhou Qiu, Andrew G. Plaut
  • CLEARANCE OF ABNORMAL IGA1 IN IGA1 DEPOSITION DISEASES
    Publication number: 20090317381
    Abstract: The present invention relates to proteins which specifically bind to IgA1 and which have been modified to comprise either O- or N-linked glycans. The invention encompasses methods for decreasing IgA1, preferably abnormally glycosylated IgA1, in an individual by administering to the individual a glycan-modified IgA1 binding protein of the invention. The invention also encompasses a method for the treatment of a disease characterized by IgA1 deposition wherein a glycan-modified IgA1 binding protein is administered to an individual in need thereof.
    Type: Application
    Filed: November 17, 2006
    Publication date: December 24, 2009
    Applicant: TUFTS MEDICAL CENTER
    Inventors: Andrew G. Plaut, Jiazhou Qiu
  • Tagged IgA1 proteases
    Publication number: 20090130084
    Abstract: The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are provided. In particular, therapeutic agents to treat IgA nephropathy, Dermatitis herpetiformis (DH), and Henoch-Schoenlein purpura (HS) are disclosed.
    Type: Application
    Filed: July 21, 2008
    Publication date: May 21, 2009
    Applicant: TUFTS MEDICAL CENTER
    Inventors: Andrew G. Plaut, Jiazhou Qiu
  • Combination therapy with IgA1 proteases
    Publication number: 20090041746
    Abstract: The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are provided. In particular, therapeutic agents to treat IgA nephropathy, Dermatitis herpetiformis (DH), and Henoch-Schoenlein purpura (HS) are disclosed.
    Type: Application
    Filed: July 21, 2008
    Publication date: February 12, 2009
    Applicant: TUFTS MEDICAL CENTER
    Inventors: Andrew G. Plaut, Jiazhou Qiu
  • Treatment of IgA1 deposition diseases
    Patent number: 7407653
    Abstract: The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are provided. In particular, therapeutic agents to treat IgA nephropathy, Dermatitis herpetiformis (DH), and Henoch-Schoenlein purpura (HS) are disclosed.
    Type: Grant
    Filed: August 19, 2004
    Date of Patent: August 5, 2008
    Assignee: Tufts Medical Center, Inc.
    Inventors: Andrew G. Plaut, Jiazhou Qiu
  • Treatment of IgA1 deposition diseases
    Publication number: 20050136062
    Abstract: The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are provided. In particular, therapeutic agents to treat IgA nephropathy, Dermatitis herpetiformis (DH), and Henoch-Schoenlein purpura (HS) are disclosed.
    Type: Application
    Filed: August 19, 2004
    Publication date: June 23, 2005
    Inventors: Andrew Plaut, Jiazhou Qiu
  • Compositions and methods for proteolytically inactivating infectious agents using lactoferrin and related molecules
    Publication number: 20020165128
    Abstract: A method for substantially reducing the pathogenicity of an infectious agent, without killing the infectious agent, by removing or degrading a surface protein of the infectious agent, by contacting the infectious agent with substantially pure, non-pasteurized, naturally occurring lactoferrin under conditions sufficient to remove or degrade the protein, is disclosed.
    Type: Application
    Filed: December 13, 2001
    Publication date: November 7, 2002
    Inventors: Andrew G. Plaut, Jiazhou Qiu, Joseph W. St. Geme